Ipilimumab associated colitis: An Ipi Colitis case series at Med Star Georgetown University Hospital

作     者：Pawan Rastogi Mohamed Sultan Aline J Charabaty Michael B Atkins Mark C Mattar 

作者机构：Department of MedicineMedS tar Georgetown University Hospital Department of GastroenterologyMedS tar Georgetown University Hospital Department of OncologyGeorgetown Lombardi Comprehensive Cancer Center 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2015年第21卷第14期

页      面：4373-4378页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Supported by Med Star Georgetown University Hospital Washington DC United States 

主　　题：Colitis Ipilimumab Immunology Infliximab Immune-re 

摘      要：Although ipilimumab has been shown to improve survival in patients with metastatic melanoma and cause regression of metastatic renal cell carcinoma, the associated immune-related toxicities are of *** resultant T cell activation by this monoclonal antibody causes an increased immune response, which has been associated with many immune-regulated adverse *** of the most concerning effects is the development of *** to 8% of patients have been reported to develop colitis, with 5% being severe(Grades 3-4).While initial treatment of such adverse effects is generally comprised of supportive and symptomatic treatment, more severe cases warrant the use of high dose ***, use of anti-TNF agents is usually reserved for those cases that prove to be refractory to *** describe a systematic case review of seven patients who developed gastrointestinal symptoms following initiation of ipilimumab immunotherapy, and present the steps in their evaluation, treatment and outcomes at our institution.